Cardiac Amyloidosis Presenting as Congestive Heart Failure: A Case Report and Literature Review
Published: 2023-11-08
Page: 401-407
Issue: 2023 - Volume 6 [Issue 1]
Ovaga B. E. *
Department of Cardiology, University Hospital Center IBN ROCHD, Casablanca, Morocco.
Charif H.
Department of Cardiology, University Hospital Center IBN ROCHD, Casablanca, Morocco.
Charkaoui I.
Department of Cardiology, University Hospital Center IBN ROCHD, Casablanca, Morocco.
P. M. Mulendele
Department of Cardiology, University Hospital Center IBN ROCHD, Casablanca, Morocco.
Abbassi I.
Department of Cardiology, University Hospital Center IBN ROCHD, Casablanca, Morocco.
Haboub M.
Department of Cardiology, University Hospital Center IBN ROCHD, Casablanca, Morocco.
Drighil A.
Department of Cardiology, University Hospital Center IBN ROCHD, Casablanca, Morocco.
Habbal R.
Department of Cardiology, University Hospital Center IBN ROCHD, Casablanca, Morocco.
*Author to whom correspondence should be addressed.
Abstract
Amyloidosis is a systemic disease characterized by extracellular infiltration of amyloid fibrils. Cardiac involvement, marked by nonspecific clinical signs, significantly influences prognosis. Initially considered rare, this involvement is increasingly diagnosed through imaging techniques, including magnetic resonance imaging (MRI), which allows for improved characterization of myocardial tissue. We present the case of a 61-year-old patient who exhibited congestive heart failure attributed to cardiac amyloidosis. The diagnosis was suspected due to concentric left ventricular hypertrophy (LVH), myocardial sparkling appearance, and concentric coiled pattern in global longitudinal strain, as revealed in imaging. MRI strengthened the sensitivity of transthoracic echocardiography by identifying myocardial infiltration. Bone scintigraphy showed no signs of increased bone uptake. The biochemical assessment supported the presence of monoclonal gammopathy.
Keywords: Cardiac amyloidosis, heart failure, ventricular hypertrophy, cardiomyopathy
How to Cite
Downloads
References
Damy T, Kristen AV, Suhr OB, Maurer MS, Planté-Bordeneuve V, Yu CR, et al. Transthyretin cardiac amyloidosis in continental Western Europe: An insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). European Heart Journal. 2022;43(5):391‑400.
Grogan M, Dispenzieri A, Gertz MA. Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response. Heart. 2017;103(14):1065‑72.
Damy T, Maurer MS, Rapezzi C, Planté-Bordeneuve V, Karayal ON, Mundayat R, et al. Clinical, ECG and echocardiographic clues to the diagnosis of TTR-related cardiomyopathy. Open Heart. 2016;3(1): e000289.
Rosenblum H, Castano A, Alvarez J, Goldsmith J, Helmke S, Maurer MS. TTR Stabilizers are Associated with Improved Survival in Patients with Transthyretin Cardiac Amyloidosis. Circulation Heart failure. 2018;11(4):e004769.
Yadav JD, Othee H, Chan KA, Man DC, Belliveau PP, Towle J. Transthyretin Amyloid Cardiomyopathy-Current and Future Therapies. Ann Pharmacother. 2021;55(12):1502‑14.
Damy T, Kristen AV, Suhr OB, Maurer MS, Planté-Bordeneuve V, Yu CR, et al. Transthyretin cardiac amyloidosis in continental Western Europe: An insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS). European Heart Journal. 2022;43(5):391‑400.
Escher F, Senoner M, Doerler J, Zaruba MM, Messner M, Mussner-Seeber C, et al. When and how do patients with cardiac amyloidosis die? Clin Res Cardiol. 2020; 109(1):78‑88.
Sperry BW, Vranian MN, Hachamovitch R, Joshi H, Ikram A, Phelan D, et al. Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis. J Am Heart Assoc. 2016;5(3):e002877.
Garcia-Pavia P, Rapezzi C, Adler Y, Arad M, Basso C, Brucato A, et al. Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur J Heart Fail. 2021;23(4): 512‑26.
Ternacle J, Bodez D, Guellich A, Audureau E, Rappeneau S, Lim P, et al. Causes and Consequences of Longitudinal LV Dysfunction Assessed by 2D Strain Echocardiography in Cardiac Amyloidosis. JACC Cardiovasc Imaging. févr. 2016; 9(2):126‑38.
Murtagh B et al0 Electrocardiographic findings in primary systemic amyloidosis and biop sy-proven cardiac involvement. Am J Cardiol. 2005;95:535-7.
Buss SJ et al. Longitudinal left ventricular function for prediction of survival in sytemic light-chain amyloidosis: Incremental value compared with clinical and biochemical markers. J AM Coll Cardiol. 2012;60:1067-76.
Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, et al. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015;132(16):1570‑9.
Masson E. EM-Consulte. Intérêt de la scintigraphie osseuse dans le diagnostic de l’amylose cardiaque. Disponible sur Available:https://www.em-consulte.com/article/1506973/interet-de-la-scintigraphie-osseuse-dans-le-diagno [Access on 15 août 2023].
Bézard M, Kharoubi M, Galat A, Le Bras F, Poullot E, Molinier-Frenkel V, et al. Real-Life Evaluation of an Algorithm for the Diagnosis of Cardiac Amyloidosis. Mayo Clin Proc. 2023;98 (1):48‑59.
Rapezzi C, Aimo A, Serenelli M, Barison A, Vergaro G, Passino C, et al. Critical Comparison of Documents From Scientific Societies on Cardiac Amyloidosis: JACC State-of-the-Art Review. J Am Coll Cardiol. 2022;79(13):1288‑303.
Fine NM, Davis MK, Anderson K, Delgado DH, Giraldeau G, Kitchlu A, et al. Canadian Cardiovascular Society/ Canadian Heart Failure Society Joint Position Statement on the Evaluation and Management of Patients With Cardiac Amyloidosis. Can J Cardiol. 2020; 36(3):322‑34.
Witteles RM, Liedtke M. AL Amyloidosis for the Cardiologist and Oncologist. JACC: CardioOncology. sept. 2019;1(1):117‑30.